Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Filtros aplicados
Base de dados
Intervalo de ano de publicação
1.
Nutr. hosp ; 35(6): 1394-1400, nov.-dic. 2018. tab, graf
Artigo em Inglês | IBECS | ID: ibc-181482

RESUMO

Background: patients with cervical cancer (CC) receiving chemotherapy and radiotherapy have several gastrointestinal adverse effects. Objective: to evaluate the effect of dietary symbiotic supplementation on fecal calprotectin (FCP), bacterial DNA levels, and gastrointestinal adverse effects in patients with CC. Methods: clinical, controlled, randomized, double-blind trial. Patients consumed symbiotics or placebo three times a day for seven weeks. FCP was assessed by Elisa method. DNA from probiotic and pathogenic bacteria were determined by quantitative real-time polymerase chain reaction. Diarrheal evacuations were evaluated with the Bristol stool form scale and nausea and vomiting were measured using the scale of the National Institute of Cancerology of the United States. Results: after a seven-week treatment, FCP concentration was lower in the symbiotic group compared to the control group (p < 0.001). Stool consistency in the placebo and symbiotic groups was similar at baseline. A significant improvement in stool consistency was obtained in both groups at the end of the intervention (p < 0.001). The concentrations and total proportions of the probiotic and pathogenic bacteria were similar in both groups. Nausea significantly diminished in both groups (p < 0.001) at the end of the trial. Furthermore, the symbiotic group had a statistically significant decrease in the frequency and intensity of vomiting when compared to the control group (p < 0.001). Conclusions: the symbiotic treatment decreases significantly the FCP levels and the frequency and intensity of vomiting in patients with CC


Introducción: los pacientes con cáncer cervical (CC) tratados con quimioterapia y radioterapia tienen frecuentemente efectos gastrointestinales adversos (EGA). Objetivo: evaluar el efecto de la suplementación dietética con simbióticos en la calprotectina fecal (FCP), el DNA bacteriano y sobre los EGA en pacientes con CC. Métodos: se realizó un ensayo clínico, aleatorizado y doble ciego. Los pacientes ingirieron simbióticos o placebo tres veces al día durante siete semanas. La FCP se evaluó mediante el método de ELISA. El ADN bacteriano se cuantificó mediante PCR en tiempo real. Las evacuaciones se evaluaron con la escala de Bristol y las náuseas y los vómitos se cuantificaron utilizando la escala del Instituto Nacional de Cancerología (USA). Resultados: después de siete semanas de tratamiento, la concentración de FCP fue menor en el grupo tratado con simbióticos en comparación al grupo control (p < 0,001). La consistencia de las heces en los grupos tratados con placebo y simbióticos fue similar al inicio del estudio. Se obtuvo una mejora significativa en la consistencia de las heces en ambos grupos al final de la intervención (p < 0,001). Los niveles de las bacterias probióticas y patogénicas fueron similares en ambos grupos. Los casos de náuseas disminuyeron en ambos grupos (p < 0,001) y el grupo tratado con simbióticos tuvo una disminución significativa en la frecuencia e intensidad de los vómitos en comparación al grupo control (p < 0,001). Conclusiones: el tratamiento simbiótico disminuye significativamente los niveles de FCP y la frecuencia e intensidad del vómito en pacientes con CC


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Fezes/química , Fezes/microbiologia , Complexo Antígeno L1 Leucocitário/análise , Prebióticos/administração & dosagem , Probióticos/administração & dosagem , Neoplasias do Colo do Útero/complicações , Neoplasias do Colo do Útero/terapia , Antineoplásicos/efeitos adversos , Bifidobacterium/genética , DNA Bacteriano/análise , Suplementos Nutricionais , Método Duplo-Cego , Escherichia coli/genética , Gastroenteropatias/etiologia , Gastroenteropatias/prevenção & controle , Inflamação/etiologia , Inflamação/prevenção & controle , Lactobacillales/genética , Placebos , Radioterapia/efeitos adversos , Salmonella/genética
2.
Int. microbiol ; 14(2): 103-110, jun. 2011. tab, graf, ilus
Artigo em Inglês | IBECS | ID: ibc-164538

RESUMO

Bacteriocins produced by Lactobacillus salivarius have been recently recognized as a natural means to control Campylobacter and Salmonella in live poultry. This finding is of relevance since Campylobacter jejuni and Campylobacter coli are the predominant species isolated from poultry that are associated with human campylobacteriosis. In the present work, lactic acid bacteria (LAB) isolated from the cecum of twenty Tunisian chickens were identified and those isolates with antagonism against Campylobacter were further characterized. Following their preliminary confirmation as LAB, 150 strains were identified by combining morphological criteria, biochemical tests, and molecular methods, the latter inluding intergenic 16S- 23S PCR, specific lactobacilli PCR, and a biphasic approach. Most of the LAB isolated belonged to the genus Lactobacillus, among them Lb. sakei (33.3%), Lb. salivarius (19.4%), Lb. reuteri (8.6%), and Lb. curvatus (8.6%). The other LAB strains included those of the genus Weissella (16.7%), Enterococcus faecalis (5.3%), Leuconostoc mesenteroides (2.7%), Lactococcus graviae (2.7%), and Streptococcus sp. (2.7%). The Lactobacilli strains were tested for their antagonism against C. jejuni and C. coli. The activity of three of them, Lb. salivarius SMXD51, Lb. salivarius MMS122, and Lb. salivarius MMS151, against the aforementioned target strains could be ascribed to the production of bacteriocins (AU)


No disponible


Assuntos
Animais , Antibiose , Campylobacter coli/crescimento & desenvolvimento , Campylobacter jejuni/crescimento & desenvolvimento , Lactobacillales/fisiologia , Ceco/microbiologia , Técnicas de Tipagem Bacteriana , Bacteriocinas/metabolismo , Tunísia , DNA Bacteriano , DNA Ribossômico , Galinhas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA